DYANAVEL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Dyanavel, and what generic alternatives are available?
Dyanavel is a drug marketed by Tris Pharma Inc and is included in two NDAs. There are eleven patents protecting this drug.
The generic ingredient in DYANAVEL is amphetamine; amphetamine aspartate/dextroamphetamine sulfate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the amphetamine; amphetamine aspartate/dextroamphetamine sulfate profile page.
DrugPatentWatch® Generic Entry Outlook for Dyanavel
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DYANAVEL?
- What are the global sales for DYANAVEL?
- What is Average Wholesale Price for DYANAVEL?
Summary for DYANAVEL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Drug Prices: | Drug price information for DYANAVEL |
| DailyMed Link: | DYANAVEL at DailyMed |
US Patents and Regulatory Information for DYANAVEL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tris Pharma Inc | DYANAVEL XR | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | SUSPENSION, EXTENDED RELEASE;ORAL | 208147-001 | Oct 19, 2015 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Tris Pharma Inc | DYANAVEL XR 20 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-004 | Nov 4, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Tris Pharma Inc | DYANAVEL XR 5 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-001 | Nov 4, 2021 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
